LU92550I2 - Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables - Google Patents

Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables Download PDF

Info

Publication number
LU92550I2
LU92550I2 LU92550C LU92550C LU92550I2 LU 92550 I2 LU92550 I2 LU 92550I2 LU 92550 C LU92550 C LU 92550C LU 92550 C LU92550 C LU 92550C LU 92550 I2 LU92550 I2 LU 92550I2
Authority
LU
Luxembourg
Prior art keywords
lurasidone
optionally
pharmaceutically acceptable
acceptable salts
free base
Prior art date
Application number
LU92550C
Other languages
English (en)
French (fr)
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92550(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of LU92550I2 publication Critical patent/LU92550I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU92550C 2005-05-26 2014-09-18 Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables LU92550I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005153508 2005-05-26

Publications (1)

Publication Number Publication Date
LU92550I2 true LU92550I2 (fr) 2015-11-02

Family

ID=37452103

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92550C LU92550I2 (fr) 2005-05-26 2014-09-18 Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables

Country Status (21)

Country Link
US (5) US8729085B2 (xx)
EP (2) EP2422783B1 (xx)
JP (2) JP4733120B2 (xx)
KR (2) KR101552033B1 (xx)
CN (2) CN101184489B (xx)
AU (1) AU2006250340C1 (xx)
BR (2) BRPI0611409B8 (xx)
CA (1) CA2606510C (xx)
CY (2) CY1114118T1 (xx)
DK (2) DK2422783T3 (xx)
ES (2) ES2408687T3 (xx)
FR (1) FR14C0069I2 (xx)
HU (1) HUS1400051I1 (xx)
LU (1) LU92550I2 (xx)
MX (1) MX2007014872A (xx)
NL (1) NL300690I2 (xx)
PL (1) PL1884242T3 (xx)
PT (1) PT1884242E (xx)
RU (1) RU2398586C3 (xx)
SI (1) SI1884242T1 (xx)
WO (1) WO2006126681A1 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633088T3 (es) 2005-05-18 2017-09-19 Sumitomo Dainippon Pharma Co., Ltd. Comprimido estable que contiene droxidopa
CN101184489B (zh) * 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物
US8673353B2 (en) * 2008-02-11 2014-03-18 Dainippon Sumitomo Pharma Co., Ltd Tablet having improved elution properties
WO2009151072A1 (ja) 2008-06-13 2009-12-17 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
JP5694773B2 (ja) * 2008-09-30 2015-04-01 テバ製薬株式会社 圧縮成型製剤およびその製造方法
MX342330B (es) 2009-05-19 2016-09-26 Celgene Corp Formulaciones de 4-amino-2-(2, 6-dioxopiperidin-3-il) isoindolin-1, 3-diona.
CN107625728A (zh) * 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012156981A1 (en) 2011-05-13 2012-11-22 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
US20140243383A1 (en) 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN103536568B (zh) * 2012-07-12 2016-12-07 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EP3318279A1 (en) * 2016-11-02 2018-05-09 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of lurasidone hydrochloride
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (ja) 2018-02-28 2019-09-06 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
PL3772992T3 (pl) 2018-04-10 2022-10-31 Freshfoodz Gmbh Sposób konserwowania posiłku przygotowanego przez podgrzewanie i dostarczania żywienia zbiorowego
JP7585043B2 (ja) * 2018-04-13 2024-11-18 サムヤン ホールディングス コーポレイション レナリドミドを含む医薬組成物
CA3153004A1 (en) * 2019-09-25 2021-04-01 Nobelpharma Co., Ltd. Granule having masked unpleasant taste and method for producing same
CN115843243B (zh) * 2020-08-26 2025-09-05 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
MX2023007601A (es) * 2020-12-23 2023-07-10 Sumitomo Pharma Co Ltd Preparacion solida oral.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
JP4105762B2 (ja) 1995-02-28 2008-06-25 アベンティス・ファーマスーティカルズ・インコーポレイテツド ピペリジノアルカノール化合物のための医薬組成物
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
BR9814090A (pt) 1997-10-20 2000-10-03 Dainippon Pharmaceutical Co Composição de drogas rapidamente solúvel
JP4063386B2 (ja) * 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
HU230440B1 (hu) * 1999-03-31 2016-06-28 Janssen Pharmaceutica N.V Előgélesített keményítőt tartalmazó szabályozott felszabadulású készítmények
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
WO2001076557A1 (fr) * 2000-04-10 2001-10-18 Sumitomo Pharmaceuticals Co., Ltd. Preparations a liberation prolongee
CA2824077C (en) 2000-09-22 2016-01-26 Dainippon Sumitomo Pharma Co., Ltd. Oral preparations with favorable disintegration characteristics
WO2002074743A1 (fr) 2001-03-19 2002-09-26 Dainippon Pharmaceutical Co., Ltd. Compose alicyclique a substitution aryle et composition medicale contenant ce compose
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004017973A1 (ja) * 2002-08-22 2004-03-04 Sumitomo Pharmaceuticals Company, Limited 統合失調症治療剤
CA2494707A1 (en) 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
WO2004078173A1 (ja) * 2003-02-05 2004-09-16 Shionogi & Co., Ltd. 溶出性の改善された錠剤
TWI344363B (en) 2003-09-12 2011-07-01 Amgen Inc Rapid dissolution formulation of a calcium receptor-active compound
EP1695699A4 (en) 2003-12-09 2012-08-22 Dainippon Sumitomo Pharma Co MEDICINAL GRAINS AND THE GRAINS CONTAINING SOLID PREPARATIONS
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CN101184489B (zh) * 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物

Also Published As

Publication number Publication date
CA2606510C (en) 2014-07-22
DK2422783T3 (en) 2015-05-11
PT1884242E (pt) 2013-05-21
AU2006250340A1 (en) 2006-11-30
ES2535478T3 (es) 2015-05-12
RU2398586C2 (ru) 2010-09-10
KR20080012306A (ko) 2008-02-11
RU2007148997A (ru) 2009-07-10
CN102048734B (zh) 2013-11-20
BRPI0611409A8 (pt) 2015-12-15
BRPI0611409A2 (pt) 2010-11-23
WO2006126681A1 (ja) 2006-11-30
US20090143404A1 (en) 2009-06-04
US9907794B2 (en) 2018-03-06
DK1884242T3 (da) 2013-05-06
US20140235651A1 (en) 2014-08-21
EP2422783B1 (en) 2015-04-08
BRPI0611409B8 (pt) 2021-05-25
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
BR122020005056A8 (pt) 2022-11-22
JPWO2006126681A1 (ja) 2008-12-25
JP5285105B2 (ja) 2013-09-11
PL1884242T3 (pl) 2013-09-30
JP4733120B2 (ja) 2011-07-27
US20150056284A1 (en) 2015-02-26
US8883794B2 (en) 2014-11-11
KR101552033B1 (ko) 2015-09-09
US9555027B2 (en) 2017-01-31
KR20130122019A (ko) 2013-11-06
US20150265611A1 (en) 2015-09-24
FR14C0069I2 (fr) 2015-11-20
BRPI0611409B1 (pt) 2020-12-29
JP2011126915A (ja) 2011-06-30
MX2007014872A (es) 2008-02-15
EP1884242A4 (en) 2009-07-01
CN102048734A (zh) 2011-05-11
EP1884242B1 (en) 2013-04-17
BR122020005056B1 (pt) 2023-01-10
US8729085B2 (en) 2014-05-20
SI1884242T1 (sl) 2013-07-31
AU2006250340B2 (en) 2012-02-09
CN101184489A (zh) 2008-05-21
CN101184489B (zh) 2011-01-19
NL300690I2 (nl) 2017-11-02
HUS1400051I1 (hu) 2016-10-28
ES2408687T3 (es) 2013-06-21
CY1114118T1 (el) 2016-06-22
FR14C0069I1 (fr) 2014-10-24
RU2398586C3 (ru) 2017-10-04
KR101380088B1 (ko) 2014-04-10
EP2422783A1 (en) 2012-02-29
HK1108379A1 (en) 2008-05-09
AU2006250340C1 (en) 2014-06-12
CA2606510A1 (en) 2006-11-30
BR122020005056A2 (xx) 2010-11-23
US20180161322A1 (en) 2018-06-14
EP1884242A1 (en) 2008-02-06

Similar Documents

Publication Publication Date Title
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
LU92035I2 (fr) Vemurafenib et les sels pharmaceutiquement acceptables de celui-ci, sous toutes les formes bénéficiant de la protection conférée par le brevet de base
FR22C1008I1 (fr) Composition immunogène
LU92200I1 (fr) Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables
LU92374I2 (fr) Alogliptin sous toutes ses formes telles que protégées par le brevet de base
LU92327I2 (fr) Ponatinib sous toutes ses formes telles que protégées par le brevet de base
LU92376I2 (fr) Alogliptin sous toutes ses formes telles que protégées par le brevet de base, combiné avec pioglitazone sous toutes ses formes telles que protégées par le brevet de base
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
LU92595I2 (fr) Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
LU92137I2 (fr) Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
RS50611B (sr) "BEZILAT SO 7 - (2- (4- (3 – TRIFLUOROMETIL - FENIL) -1, 2, 3, 6" TETRAHIDRO - PIRID-1- ILI)ETIL)IZOHINOLlNA, NJENO DOBIJANJE I NJENA TERAPEUTSKA PRIMENA
DE602006000763D1 (de) Kissenkörper
PL378587A1 (pl) Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli
EP1846024A4 (en) Mycobacterial mutants affecting host apoptosis
ITBO20040561A1 (it) Macchina per la lavorazione di lamiere
FR2881048B1 (fr) Composition parfumante sous forme compactee
ITMI20051435A1 (it) Macchina per la realizzazione di capi di abbigliamento e simili
FR2884969B1 (fr) Integration d'elements capacitifs sous forme de ceramique perovskite
ITMI20040443A1 (it) Prpcesso per la preparazione di ..15-16-17-cheto-steroidi e loro uso nella sintesi di composti farmacologicamente attivi
ITMI20040505A1 (it) Macchina per la frantumazione di bottiglie
FR2886642B1 (fr) Sels alcalino-terreux d'irbesartan et leur preparation
ITMI20062515A1 (it) Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
ITVR20030013A1 (it) Procedimento per l'ottenimento di lastre dotate di
ES1061876Y (es) Flexometro perfeccionado de uña giratoria.
ITBS20050150A1 (it) Macchina per la sublimazione